HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17

2007 ◽  
Vol 43 (16) ◽  
pp. 2339-2344 ◽  
Author(s):  
Rosalba Torrisi ◽  
Nicole Rotmensz ◽  
Vincenzo Bagnardi ◽  
Giuseppe Viale ◽  
Barbara Del Curto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Early Breast Cancer ◽  
Her2 Status ◽  
Polysomy 17 ◽  
Cell Staining

scholarly journals Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer

2021 ◽  
Author(s):  
Tilman D. Rachner ◽  
Sabine Kasimir-Bauer ◽  
Andy Goebel ◽  
Kati Erdmann ◽  
Oliver Hoffmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Poor Prognosis ◽  
Therapeutic Potential ◽  
Transmembrane Protein ◽  
Tumor Biology ◽  
Tumor Stage ◽  
Her2 Status ◽  
Tyrosine Kinase Receptor ◽  
Neuropilin 1

Abstract Background Neuropilin-1 (NRP-1) is a transmembrane protein that acts as a multifunctional non-tyrosine kinase receptor with an established role in development and immunity. NRP-1 also regulates tumor biology, and high expression levels of tissue NRP-1 have been associated with a poor prognosis. Recently, ELISA-based quantification of soluble NRP-1 (sNRP-1) has become available, but little is known about the prognostic value of sNRP-1 in malignancies. Materials and methods We measured sNRP-1 in the serum of 509 patients with primary early breast cancer (BC) at the time of diagnosis using ELISA. Results Mean serum values of sNRP-1 were 1.88 ± 0.52 nmol/l (= 130.83 ± 36.24 ng/ml). SNRP-1 levels weakly correlated with age, and were higher in peri- and postmenopausal patients compared to premenopausal patients, respectively (p < 0.0001). Low levels of sNRP-1 were associated with a significant survival benefit compared to high sNRP-1 levels at baseline (p = 0.005; HR 1.94; 95%CI 1.23–3.06). These findings remained significant after adjustment for tumor stage including lymph node involvement, grading, hormone receptor, HER2 status, and age (p = 0.022; HR 1.78; 95%CI 1.09–2.91). Conclusion Our findings warrant further investigations into the prognostic and therapeutic potential of sNRP-1 in BC.

scholarly journals Moderate Immunohistochemical Expression of HER‐2 (2+) Without HER‐2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer

2012 ◽  
Vol 17 (11) ◽  
pp. 1418-1425 ◽  
Author(s):  
Valentina Rossi ◽  
Ivana Sarotto ◽  
Furio Maggiorotto ◽  
Paola Berchialla ◽  
Franziska Kubatzki ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Gene Amplification ◽  
Early Breast Cancer ◽  
Immunohistochemical Expression ◽  
Negative Prognostic Factor ◽  
Her 2

Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer

2012 ◽  
Vol 18 (4) ◽  
pp. 885-894 ◽  
Author(s):  
Anna Żaczek ◽  
Aleksandra Markiewicz ◽  
Anna Supernat ◽  
Natalia Bednarz-Knoll ◽  
Burkhardt Brandt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Amplification ◽  
Early Breast Cancer ◽  
Prognostic Value ◽  
Chromosome 17 ◽  
Top2a Gene

scholarly journals Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre

2017 ◽  
Vol 06 (02) ◽  
pp. 045-046
Author(s):  
Manoj Kumar Panigrahi ◽  
Dushyant Kumar ◽  
Anurag Mehta ◽  
Kandarpa Kumar Saikia
Keyword(s):  
Breast Cancer ◽  
Final Analysis ◽  
Chromosome 17 ◽  
Research Centre ◽  
Her2 Status ◽  
Her2 Positive ◽  
Her2 Testing ◽  
Polysomy 17 ◽  
Cancer Experience ◽  
The Impact

Abstract Background and Objectives: HER2 testing guideline of ASCO/CAP for interpretation and reporting has recently been revised. The study is aimed to measure the impact of 2013 CAP guideline on equivocal HER2 test outcome (immunohistochemistry [IHC] 2+) when tested by fluorescent in situ hybridization (FISH). The study also aims at finding the frequency of polysomy and monosomy of chromosome 17. Materials and Methods: Specimens were collected in Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India. IHC was performed in every case, and FISH was performed in IHC2+ cases. Results: In final analysis includes 557 subjects on the basis of CAP guideline 2007 and CAP guideline 2013. One hundred ninety-two subjects (34.4%) were HER2 amplified according to CAP scoring 2007, and 246 subjects (44%) according to 2013 CAP scoring. Conclusions: FISH results were evaluated (IHC2 + interpreted according to CAP 2007 guideline) with both 2007 and 2013 ASCO/CAP scoring criteria, we identified significantly more HER2 positive cases as compared to cases evaluated using the 2007 criteria (P < 0.05). We also found that in breast carcinoma, HER2 status in the presence of polysomy 17 may vary with the scoring criteria used. Evaluation of FISH result using 2013 ASCO/CAP criteria means that more patients with breast cancer may be appropriate for targeted treatment with trastuzumab, potentially improving their outcome.

scholarly journals HER2 Testing in Invasive Breast Cancer: A Comparison Between Immunohistochemistry and Fluorescence In Situ Hybridization Assays

2020 ◽  
Vol 8 (3) ◽  
pp. 139-146
Author(s):  
Maryam Moradi Chaleshtori ◽  
◽  
Zohreh Hojati ◽  
Ali Jazaeri ◽  
Hossein Teimori ◽  
...  
Keyword(s):  
Breast Cancer ◽  
In Situ Hybridization ◽  
Fluorescence In Situ Hybridization ◽  
Gene Amplification ◽  
Invasive Breast Cancer ◽  
Concordance Rate ◽  
Her2 Status ◽  
Her2 Gene ◽  
Relative Copy Number

Background: HER2 status testing in breast cancer is crucial for the detection of eligible patients for trastuzumab therapy. In this study, the relative copy number of HER2 gene, in patients with breast cancer, was determined by fluorescence in situ hybridization (FISH) and the results were compared with those of immunohistochemistry (IHC) to obtain the concordance rate between these two methods. Material and Methods: HER2 status of 31 invasive breast cancer samples was compared using IHC and FISH techniques. The ratio of HER2/CEP17 was used to determine the amplification of the HER2 gene. If the ratio of HER2/CEP17 is greater than 2.2, HER2 gene amplification has occurred in the cancer cells. Then, a comparative analysis is performed to estimate the concordance rate between FISH and IHC results. Results: The gene amplification of HER2 was observed in 26% of cases by FISH. The IHC and FISH results showed 100%, 36.36%, and 85.71% concordance rates for cases with IHC scores of 3+, 2+, and 0/+1, respectively. The overall concordance between the two methods was 80%. Based on statistical analysis, HER2 status showed a considerable correlation with tumor grade (P= 0.02). No correlation was observed between HER2 gene status and the size and type of tumor, characteristics of lymph node, and patients’ age. Conclusion: The data suggested that IHC results are reliable for HER2 status testing in cases with IHC scores 0/+1 and 3+. However, in patients with an IHC score of +2, it is necessary to perform a complimentary test to evaluate HER2 status to avoid haphazard treatment with trastuzumab in negative cases and identifying positive cases for suitable treatment.

scholarly journals Circulating Tumor Cells in Breast Cancer Patients: An Evolving Role in Patient Prognosis and Disease Progression

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Holly Graves ◽  
Brian J. Czerniecki
Keyword(s):  
Breast Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Early Breast Cancer ◽  
Primary Tumor ◽  
Metastatic Breast ◽  
Her2 Status ◽  
Breast Cancer Patients ◽  
Neoplastic Process

In this paper, we examine the role of circulating tumor cells (CTCs) in breast cancer. CTCs are tumor cells present in the peripheral blood. They are found in many different carcinomas but are not present in patients with benign disease. Recent advances in theories regarding metastasis support the role of early release of tumor cells in the neoplastic process. Furthermore, it has been found that phenotypic variation exists between the primary tumor and CTCs. Of particular interest is the incongruency found between primary tumor and CTC HER2 status in both metastatic and early breast cancer. Overall, CTCs have been shown to be a poor prognostic marker in metastatic breast cancer. CTCs in early breast cancer are not as well studied, however, several studies suggest that the presence of CTCs in early breast cancer may also suggest a poorer prognosis. Studies are currently underway looking at the use of CTC level monitoring in order to guide changes in therapy.

Sign in / Sign up

Export Citation Format

Share Document